Related Experiment Video

Updated: May 23, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

A comprehensive overview of targeted therapy in metastatic renal cell carcinoma

Z Mihaly1, Z Sztupinszki, P Surowiak

  • 1Research Laboratory for Pediatrics and Nephrology, Hungarian Academy of Sciences - Semmelweis University 1st Dept. of Pediatrics, Wrocaw University School of Medicine, ul. Chaubińskiego 6a, 50-356 Wrocaw, Poland

Current Cancer Drug Targets
|April 21, 2012
PubMed

Insights

Systemic treatments for metastatic renal cell carcinoma, including chemotherapy and immunotherapy, show limited success. Current therapies target the RAS pathway, with ongoing trials exploring novel kinase inhibitors and antibodies for improved survival benefits.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic renal cell carcinoma (mRCC) systemic treatment remains challenging, with chemotherapy and immunotherapy yielding suboptimal results.
  • Current standard therapies primarily target the RAS signal transduction pathway, including vascular endothelial growth factor inhibitors, mTOR inhibitors, and multi-targeted receptor tyrosine kinase inhibitors.

Purpose of the Study:

  • To provide a comprehensive overview of current advances in the systemic treatment of metastatic renal cell carcinoma.
  • To review clinical investigation results focusing on survival benefits of existing and novel therapeutic agents.

Main Methods:

  • Review of published clinical investigation results for established mRCC therapies.
  • Inclusion of follow-up and interim results from ongoing clinical trials of new agents.
  • Discussion of emerging therapies including kinase inhibitors (axitinib, tivozanib, dovitinib, cediranib) and monoclonal antibodies (velociximab).

Main Results:

  • Established first-line therapies include sunitinib, temsirolimus, pazopanib, and bevacizumab plus interferon α.
  • Second-line treatment options comprise everolimus and tyrosine kinase inhibitors for patients previously treated with cytokines.
  • Emerging agents show promise, with ongoing trials evaluating their efficacy and survival impact.

Conclusions:

  • Current systemic treatments for mRCC offer survival benefits but are not always decisive.
  • Novel kinase inhibitors and monoclonal antibodies represent promising future directions in mRCC therapy.
  • Continuous evaluation of clinical trial data is crucial for advancing mRCC treatment strategies.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...